


| | | |
|---|----------------------------------|------------------------------------|
|  | M40 - VERAPAMIL (ISOPTIN) | |
| | Version date: 2025-11-17 | EFFECTIVE DATE: 2026-01-06 (07:00) |
| ERS HIGH ALERT MEDICATION (A03) | | |

| INDICATIONS |
|---|
| <ul style="list-style-type: none"> • Rate control in atrial fibrillation or flutter as an alternative to beta blockade (table A) • Supraventricular re-entrant tachycardia (e.g. PSVT) where adenosine has been ineffective or the rhythm has recurred after adenosine administration (table B) |

| WARNINGS |
|--|
| <p>ABSOLUTE CONTRAINDICATIONS:</p> <ul style="list-style-type: none"> • Hypersensitivity to verapamil • Unstable hemodynamics • Wide complex tachycardia • Known or suspected preexcitation (e.g. Wolff-Parkinson-White syndrome) • Known or suspected sick sinus syndrome |
| <p>USE WITH CAUTION:</p> <ul style="list-style-type: none"> • Prior administration of beta blocker or amiodarone ¹ • Cirrhosis ² |

| TABLE A: ATRIAL FIBRILLATION / FLUTTER | |
|---|-----|
| INTRAVENOUS (INTRAOSSEOUS) INJECTION | ACP |
| <p>ADULTS:</p> <ul style="list-style-type: none"> • 5 to 10 mg • Administer by slow push over 2 minutes • If there is an inadequate response after 15 to 30 minutes, repeat 5 to 10 mg once • If there is an adequate response after one or two doses, begin a continuous infusion | |
| INTRAVENOUS (INTRAOSSEOUS) INFUSION | ACP |
| <p>ADULTS:</p> <ul style="list-style-type: none"> • Begin at 5 mg/hr • Titrate in increments of 5 mg/hr every 15 minutes as required • Maximum infusion rate = 20 mg/hr | |

TABLE B: SUPRAVENTRICULAR TACHYCARDIA

INTRAVENOUS (INTRAOSSEOUS) INJECTION

ACP

ADULTS:

- 5 to 10 mg
- Administer by slow push over 2 minutes
- If there is an inadequate response after 15 to 30 minutes, repeat 5 to 10 mg once

NOTES

1. The effects of verapamil and other atrioventricular nodal blocking agents (e.g. beta blockers, amiodarone) can be cumulative leading to severe hypotension or heart block. Administer with caution.
2. Reduce the dose by 50 percent in patients with cirrhosis or severe hepatic impairment.

LINKS

- A03 - High Alert Medications
- C06 - Tachycardia

APPROVED BY


EMS Medical Director



EMS Associate Medical Director

VERSION CHANGES (refer to X08 for change tracking)

- New (replaces M10 - Diltiazem)